Curaleaf price target raised to $7 from $4 at Roth MKM

Roth MKM raised the firm’s price target on Curaleaf to $7 from $4 and keeps a Buy rating on the shares ahead of its Q4 results. The firm sees slightly higher revenue and EBITDA growth due to leading market positioning in key states – Maryland and New Jersey – and better cost controls, offset by price pressures and facility underutilization, the analyst tells investors in a research note.